Clinical Report: Real-World Imaging Confirms Faricimab Response in DME

Overview

The VOYAGER study demonstrates that faricimab leads to significant reductions in intraretinal and subretinal fluid in patients with diabetic macular edema (DME) within the first six months of treatment. This real-world evidence aligns with findings from randomized controlled trials, supporting the efficacy of faricimab in managing DME.

Background

Diabetic macular edema (DME) is a leading cause of vision loss in patients with diabetes, making effective treatment essential. Faricimab, a bispecific antibody, has shown promise in clinical trials, but real-world data is crucial for understanding its effectiveness in routine practice. The VOYAGER study provides valuable insights into the treatment response of faricimab in a diverse patient population across multiple countries.

Data Highlights

Key Findings

• Faricimab leads to a significant reduction in intraretinal fluid by more than 50% at one month.
• Subretinal fluid reduction approaches zero by six months in the analyzed subgroup.
• The VOYAGER study includes over 5,000 participants across 28 countries.
• ROSA, an AI-based algorithm, effectively analyzes volumetric imaging data for fluid detection.
• Findings are consistent with previous randomized controlled trials of faricimab.

Clinical Implications

The rapid reduction of fluid observed with faricimab suggests that clinicians can expect early treatment responses in patients with DME. This data supports the integration of imaging-based assessments in routine monitoring and treatment planning for DME management.

Conclusion

The VOYAGER study reinforces the efficacy of faricimab in real-world settings, highlighting its potential to improve outcomes for patients with diabetic macular edema. Ongoing analysis will further elucidate its long-term benefits.

References

1. Retinal Physician, Faricimab Shows Durable Efficacy and Safety in 2-Year DME Study, 2024 -- https://www.retinalphysician.com/issues/2024/julyaugust/faricimab-shows-durable-efficacy-and-safety-in-2-year-dme-study
2. Retinal Physician, Video: Faricimab Maintains Long-Term Stability in DME, 2025 -- https://www.retinalphysician.com/issues/2025/julyaugust/asrs12
3. Retinal Physician, Faricimab Approved by the FDA for Wet AMD and DME, 2022 -- https://retinalphysician.com/issues/2022/januaryfebruary/faricimab-approved-by-the-fda-for-wet-amd-and-dme/
4. The Ophthalmologist, Early Fluid Resolution Predicts Faricimab Durability, 2026 -- https://www.theophthalmologist.com/issues/2026/articles/april/early-fluid-resolution-predicts-faricimab-durability/
5. PubMed, Retinopathy, Neuropathy, and Foot Care: Standards of Care in Diabetes-2026 -- https://pubmed.ncbi.nlm.nih.gov/41358886?utm_source=openai
6. PubMed, Faricimab Treat-and-Extend for Diabetic Macular Edema: Two-Year Results from the Randomized Phase 3 YOSEMITE and RHINE Trials -- https://pubmed.ncbi.nlm.nih.gov/38158159/?utm_source=openai
7. Eye, Real-world treatment patterns and visual outcomes of faricimab in patients with diabetic macular oedema in the UK at 12 months: the FARWIDE-DMO study -- https://www.nature.com/articles/s41433-025-04059-8
8. Retinal Physician — Faricimab Shows Durable Efficacy and Safety in 2-Year DME Study
9. retinal physician — Video: Faricimab Maintains Long-Term Stability in DME
10. Retinal Physician — Faricimab Approved by the FDA for Wet AMD and DME
11. the ophthalmologist — Early Fluid Resolution Predicts Faricimab Durability
12. 12. Retinopathy, Neuropathy, and Foot Care: Standards of Care in Diabetes-2026 - PubMed
13. Faricimab Treat-and-Extend for Diabetic Macular Edema: Two-Year Results from the Randomized Phase 3 YOSEMITE and RHINE Trials - PubMed
14. Real-world treatment patterns and visual outcomes of faricimab in patients with diabetic macular oedema in the UK at 12 months: the FARWIDE-DMO study | Eye